Cetus Healthcare Limited Partnership II
Public offering of shares in the $100 mil. R&D partnership began Oct. 30. Proceeds will be used to fund the development of therapeutic products in Europe through the company's new subsidiary, EuroCetus ("The Pink Sheet" Aug. 25, T&G-2). Shearson Lehman Brothers and Oppenheimer are managing the sale.
You may also be interested in...
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.